AURA vs OCUL vs RCKT vs REPL

Analysts rate Aura Biosciences, Inc.

(AURA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ocular Therapeutix, Inc.

(OCUL) delivered a total return of -36. 9%, compared to -94. 2% for Rocket Pharmaceuticals, Inc. (RCKT). Over 10 years, the gap is even starker: OCUL returned +39. 7% versus RCKT's -91. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Replimune Group, Inc.

(REPL) is the lower-risk stock at 0. 84β versus Rocket Pharmaceuticals, Inc. 's 2. 06β — meaning RCKT is approximately 146% more volatile than REPL relative to the S&P 500. On balance sheet safety, Rocket Pharmaceuticals, Inc. (RCKT) carries a lower debt/equity ratio of 9% versus 18% for Replimune Group, Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Rocket Pharmaceuticals, Inc.

grew EPS 26. 4% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Aura Biosciences, Inc.

(AURA) is the more profitable company, earning 0. 0% net margin versus -513. 2% for Ocular Therapeutix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AURA leads at 0. 0% versus -521. 0% for OCUL. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Replimune Group, Inc.

(REPL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 84)). Rocket Pharmaceuticals, Inc. (RCKT) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REPL: -41. 4%, RCKT: -91. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.